Overview: Inhibitors of Enzymes Involved in Catecholamine Biosynthesis and Degradation

References to Primary Literature

• Abel JI, Crawford AC On the blood-pressure-raising constituent of the suprarenal capsule. Bull. Johns Hopkins Hosp. 1897 8 151–157.
   Google Scholar
• Takemine S The blood pressure raising principle of the suprarenal glands; a preliminary report. Therap. Gaz. s. 3 1901 16 221–225.
   Google Scholar
• Hokfelt T, Fuxe K, Goldstein M, Johansson O Evidence for adrenaline neurones in the brain. Acta Physiol. Scand. 1973 89 286–288.
   PubMedGoogle Scholar
• Von Euler US Presence of a substance with sympathin E properties in spleen extracts. Acta Physiol. Scand. 1946 105 38–43.
   Google Scholar
• Vogt M The concentration of sympathins in different parts of the central nervous system under normal conditions and after administration of drugs. J. Physiol. (London) 1954 123 441–481.
   Google Scholar
• Holtz P, Credner K, Strubing C Uber das vorkommen den dopadecarboxylase im pankreas. Arch. Exp. Path. Pharmakol. 1942 199 145–150.
   Google Scholar
• Goodall McC Dihydroxyphenylalanine and hydroxytryptamine in mammalian supra renals. Acta Chem. Scand. 1950 4 550–556.
   Google Scholar
• Metabolism of amino acids and amines. Methods in Enzymology Tabor H Tabor CW Academic Press New York 1971 XVIIA, XVIIB These two volumes discuss in detail all aspects of enzyme purification and assay conditions for the enzymes discussed in this review. More recent references are cited when each enzyme is considered individually.
   Google Scholar
• Weiner N Drugs that inhibit adrenergic nerves and block adrenergic receptors. The Pharmaceutical Basis of Therapeutics, Seventh Edition Gilman AG Goodman LS Rall TW Murad F Macmillan Publishing Company New York 1985, 210.
   Google Scholar
• El-Masry AH, El-Masry EE, Hare LE, Consell RE Aromatic amino acid hydroxylase inhibitors. 4. 3-Substituted α-methyltyrosines. J. Med. Chem. 1975 18 16–20 A representative, more recent publication looking at simple derivatives. References cite earlier work.
   PubMed Web of Science ®Google Scholar
• McDonald IA, Nyce PL, Jung MJ, Sabol JS Syntheses of DL-2-fluoromethyl-p-tyrosine and DL-2-difluoromethyl-p-tyrosine as potential inhibitors of tyrosine hydroxylase. Tetradhedron Lett. 1991 32 887–890.
   Web of Science ®Google Scholar
• Bianchine JR Drugs for Parkinson's disease, spasticity, and acute muscle spasms. The Pharmacological Basis of Therapeutics, Seventh Edition Gilman AG Goodman LS Rall TW Murad F Macmillan Publishing Company New York 1985, 480–481.
   Google Scholar
• Maycock AL, Aster SD, Patchett AA Inactivation of 3-(3,4-dihydroxyphenyl)alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine. Biochemistry 1980 19 709–718 Comprehensive study of the mechanism of inhibition.
   PubMed Web of Science ®Google Scholar
• Fozard JR, Spedding M, Palfreyman MG, Wagner J, Mohring J, Koch-Weser J Depression of sympathetic nervous function by DL-alpha-mono-fluoromethyldopa, an enzyme-activated, irreversible inhibitor of l-aromatic amino acid decarboxylase. J. Cardiovasc. Pharmacol. 1980 2 229–245 Comprehensive pharmacological study in rats.
   PubMed Web of Science ®Google Scholar
• Gardner CR, Richards MH Use of D,L-alpha-monofluoromethyldopa to distinguish subcellular pools of aromatic amino acid decarboxylase in mouse brain. Brain Res. 1981 216 291–298 Synaptosomal and nerve cell body pools of AADC are studied with this selective inhibitor.
   PubMed Web of Science ®Google Scholar
• Wagner J, Zraika M Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa. Br. J. Pharmacol. 1980 70 571–576 Demonstrates the long-lasting effect of the inhibitor on mouse brain, heart and kidney catecholamine levels.
   PubMed Web of Science ®Google Scholar
• Palfreyman MG, Zreika M, Arbogast R, Wagner J A method for measuring monamine turnover in animals using an irreversible inhibitor of aromatic L-amino acid decarboxylase, DL-alpha-monofluoromethyldopa. J. Pharmacol. Methods 1984 11 239–251.
   PubMedGoogle Scholar
• Ribéreau-Gayon G, Palfreyman MG, Zraika M, Wagner J, Jung MJ Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor. Biochem. Pharmacol. 1980 29 2465–2569.
   PubMed Web of Science ®Google Scholar
• Silverman RB Mechanism-based enzyme inactivation: Chemistry and enzymology CRC Press, Inc. 1988 II 63–68 A comprehensive review of the design of inhibitors of enzymes which catalyse decarboxylation reactions.
   Google Scholar
• Ribéreau-Gayon G, Danztn C, Palfreyman MG, Aubry M, Wagner J, Metcalf BW, Jung MJ In vitro and in vivo effects of α-acetylenic dopa and α-vinyl dopa on l-amino acid decarboxylase. Biochem. Pharmacol. 1979 28 1331–1335.
   PubMed Web of Science ®Google Scholar
• Castelhano AL, Pliura DH, Taylor GJ, Hsieh KC, Krantz A Allenic suicide substrates. New inhibitors of vitamin B6 linked decarboxylase. J. Am. Chem. Soc. 1984 106 2734.
   Web of Science ®Google Scholar
• Jung MJ, Hornsperger JM, Gerhart F, Wagner J Inhibition of aromatic amino acid decarboxylase and depletion of biogenic amines in brain of rats treated with α-monofluoromethyl-p-tyrosine: Similarities and differences from the effects of α-monofluoromethyldopa. Biochem. Pharmacol. 1984 33 327–330.
   PubMed Web of Science ®Google Scholar
• Jung MJ, Danzin C New developments in enzyme-activated irreversible inhibitors of pyridoxal phosphate-dependent enzymes of therapeutic interest. Design of Enzyme Inhibitors as Drugs Sandler M Smith RH Oxford Science Publications Oxford 1989, 257–293 An excellent review of the field which covers mechanism, enzymology, pharmacology and clinical aspects.
   Google Scholar
• Smith HJ Inhibitors of some other target enzymes as potential clinical agents. Design of Enzyme Inhibitors as Drugs Sandler M Smith HJ Oxford Science Publications Oxford 1989, 751–762 A very good review of dopamine β-hydroxylase inhibitors which cites a large number of earlier reviews.
   Google Scholar
• Claxton IM, Palfreyman MG, Poyser RH, Whiting RL BRL 8242 (2-[2-benzimidazolyl]-amino-2-imidazoline dihydrochloride), a new inhibitor of dopamine-β-hydroxylase with antihypertensive activity. Eur. J. Pharmacol. 1976 37 179–188.
   PubMed Web of Science ®Google Scholar
• May SW, Herman HH, Roberts SF, Ciccarello MC Ascorbate depletion as a consequence of product recycling during dopamine β-monooxygenase catalyzed selenoxidation. Biochemistry 1987 26 1626–1633.
   PubMed Web of Science ®Google Scholar
• May SW, Mueller PW, Padgette SR, Herman HH, Phillips RS Dopamine-β-hydroxylase: Suicide inhibition by the novel olefinic substrate, 1-phenyl-1-aminomethylethene. Biochem Biophys. Res. Comm. 1983 110 161–168.
   PubMed Web of Science ®Google Scholar
• Barger TM, Broersma RJ, Creemer LC, McCarthy JR, Hornsperger J-M, Palfreyman MG, Wagner J, Jung MJ Unsaturated heterocyclic amines as potent time-dependent inhibitors of dopamine β-hydroxylase. J. Med. Chem. 1986 29 315–317.
   PubMed Web of Science ®Google Scholar
• Kruse LI, Kaiser C, DeWolf WE Jr, Chambers PA, Goodhart PJ, Ezekiel M, Ohlstein EH Beta-substituted phenethylamines as high-affinity mechanism-based inhibitors of dopamine beta-hydroxylase. J. Med. Chem. 1988 31 704–706.
   PubMed Web of Science ®Google Scholar
• Padgette SR, Wimalasena K, Herman HH, Sirimanne SR, May SW Olefin oxygenation and N-dealkylation by dopamine β-hydroxylase: Catalysis and mechanism-based inhibition. Biochemistry 1985 24 5826–5839.
   PubMed Web of Science ®Google Scholar
• Barger TM, Broersma RJ, Creemer LC, McCarthy JR, Hornsperger J-M, Attwood PV, Jung MJ Highly effective mechanism-based inactivation of dopamine β-hydroxylase by a novel ketene thiacetal. J. Am. Chem. Soc. 1988 110 2975–2979.
   Web of Science ®Google Scholar
• Colombo G, Rajashekhar B, Giedroc DP, Villafranca JJ Mechanism-based inhibitors of dopamine β-hydroxylase: Inhibition by 2-bromo-3-(p-hydroxyphenyl)-1-propene. Biochem. 1984 23 3590–3598.
   PubMed Web of Science ®Google Scholar
• Fitzpatric PF, Villafranca JJ Mechanism-based inhibitors of dopamine β-hydroxylase containing acetylenic or cyclopropyl groups. J. Amer. Chem. Soc. 1985 107 5022–5023.
   Web of Science ®Google Scholar
• McCarthy JR, Matthews DP, Barney CL A new synthesis of 2-fluoro-1-olefins. Tetrahedron Lett. 1990 31 973–976.
   Web of Science ®Google Scholar
• Goodhart PJ, DeWolf WE Jr, Kruse LI Mechanism-based inactivation of dopamine β-hydroxylase by p-cresol and related alkyl phenols. Biochem. 1987 26 2576–2583.
   PubMed Web of Science ®Google Scholar
• Bossard MJ, Klinman JP Mechanism-based inhibition of dopamine β-monooxygenase by aldehydes and amides. J. Biol. Chem. 1986 261 16421–16427.
   PubMed Web of Science ®Google Scholar
• Kruse LI, Kaiser C, DeWolf WE, Frazee JS, Erikson RW, Ezekiel M, Ohlstein EH, Ruffollo RR Jr, Berkowitz BA Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine β-hydroxylase. J. Med. Chem. 1986 29 887–889.
   PubMed Web of Science ®Google Scholar
• Kruse LI, Kaiser C, DeWolf WE, Finkelstein JA, Frazee JS, Hilbert EL, Ross ST, Flaim KE, Sawyer JL Some benzyl-substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of dopamine β-hydroxylase. 4. Structure-activity relationships at the copper binding site. J. Med. Chem. 1990 33 781–789.
   PubMed Web of Science ®Google Scholar
• McCarthy JR, Matthews DP, Broersma RJ, McDermott RD, Kastner PR, Hornsperger J-M, Demeter DA, Weintraub HJR, Whitten JP 1-(Thienylalkyl)-imidazole-2(3H)-thiones as potent competitive inhibitors of dopamine β-hydroxylase. J. Med. Chem. 1990 33 1866–1873.
   PubMed Web of Science ®Google Scholar
• Grunewald GL, Markovich KM, Sall DJ Binding orientation of amphetamine and norfenfluramine analogues in the benzonor-bornene and benzobicydo[3.2.1]octane ring systems at the active site of phenylethanol amine N-methyltransferase (PNMT). J. Med. Chem. 1987 30 2191–2208 Full paper with a comprehensive introduction in which the physiological role of PNMT is discussed.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Molloy BB, Day WA, Roush BW, Marsh MM Inhibition of phenylethanolamine N-methyltransferase by benzylamines. J. Med. Chem. 1973 16 101–106.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Roush BW, Hemrick SK, Snoddy HD, Molloy BB Inhibition of noradrenaline N-methyltransferase by 1-aminoindans, conformationally rigid analogs of benzylamines. Life Sci. 1978 22 1421–1428.
   PubMed Web of Science ®Google Scholar
• Fuller RW, Hemrick-Luecke S, Toomey RE, Horng J-S, Ruffolo RR Jr, Molloy BB Properties of 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine, an inhibitor of nor epinephrine N-methyltransferase. Biochem Pharmacol. 1981 30 1345–1352.
   PubMed Web of Science ®Google Scholar
• Bondinell WE, Chapin FW, Girard GR, Kaiser C, Krog AJ, Pavloff AM, Schwartz MS, Silvestri JS, Vaidya PD, Lam BL, Wellman GR, Pendleton RG Inhibitors of phenylethanolamine N-methyltransferase and adrenaline biosynthesis. 1. Chloro-substituted 1,2,3,4-tetrahydroisoquinolines. J. Med. Chem. 1980 23 506–511.
   PubMed Web of Science ®Google Scholar
• Pendleton RG, Gessner G, Sawyer J Comparison of the effects of SK&F 29661 and 64139 upon adrenal and cardiac catecholamines. Eur. J. Pharmacol. 1980 68 117–127.
   PubMed Web of Science ®Google Scholar
• DeMarinis RM, Bryan WM, Hillegass LM, McDermott D, Pendleton RG Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis. 3. Bis[tetrahydroisoquinoline]s. J. Med. Chem. 1981 24 756–759.
   PubMed Web of Science ®Google Scholar
• Grunewald GL, Markovich KM, Sall DJ Binding orientation of amphetamine and norfenfluramine analogues in the benzonor-bornene and benzobicyclo[3.2.1]octane ring systems at the active site of phenylthanolamine N-methyltransferase (PNMT). J. Med. Chem. 1987 30 2191–2208.
   PubMed Web of Science ®Google Scholar
• Grunewald GL, Carter AE, Sall DJ, Monn JA Conformational preference for the binding of biaryl substrates and inhibitors to the active site of phenylethanolamine N-methyltransferase. J. Med. Chem. 1988 31 60–65.
   PubMed Web of Science ®Google Scholar
• Davis DP, Borchardt RT, Grunewald GL Importance of the aromatic ring in adrenergic amines. 6. Nonaromatic analogues of phenylethanolamine as inhibitors of phenyl ethanolamine N-methyltransferase: Role of π-electronic and steric interactions. J. Med. Chem. 1981 24 12–16.
   PubMed Web of Science ®Google Scholar
• Grunewald GL, Ye Q, Sall DJ, Criscione KR, Wise B Conformational and steric aspects of phenylethanolamine and phenylethylamine analogues as substrates or inhibitors of phenylethanolamine N-methyltransferase. Molec. Pharmacol. 1989 35 93–97.
   PubMed Web of Science ®Google Scholar
• Chatelain RE, Manntello MJ, Dardik BN, Rrzzo M, Brosnihan KB Antihypertensive effects of CGS 19281A, an inhibitor of phenylethanol-amine-N-methyltransferase. J. Pharmacol. Exp. Ther. 1990 252 117–125.
   PubMed Web of Science ®Google Scholar
• McDonald IA, Bey P, Palfreyman MG Monoamine oxidase inhibitors. Design of Enzyme Inhibitors as Drugs Sandler M Smith JH Oxford Science Publications Oxford 1989, 257–293 A comprehensive, more recent review which primarily discusses the utility of MAO inhibitors and the recent research directed towards safe compounds (i.e. free of the ‘cheese’ effect).
   Google Scholar
• Monoamine oxidase and disease Tipton KF Dostert P Benedetti Strolin M Academic Press London 1984 This book includes all papers presented at a Paris, 1983. The focus is on the prospects for therapy with reversible inhibitors.
   Google Scholar
• Monoamine oxidase: Structure, function, and altered functions Singer TP Von Korff RW Murphy DL Academic Press 1979 Although dated, this collection of chapters provides a very thorough introduction to MAO inhibitors.
   Google Scholar
• McDonald IA, Bey P, Zreika M, Palfreyman MG MDL 72,974A. Drugs of the Future 1991 16 428–431 Review of the chemistry, enzymology, pharmacology and early clinical results.
   Google Scholar
• Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinatahn G, Neophytides AN, Foo S-H, Duvoisin RC Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol. 1988 11 45–55.
   PubMed Web of Science ®Google Scholar
• Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL L-Deprenyl in Alzheimer's disease. Preliminary evidence for behavioural change with monoamine oxidase B inhibition. Arch. Gen. Psychiatry 1987 44 427–433.
   PubMed Web of Science ®Google Scholar
• Cruces MA, Elorriage C, Fernández-Alvarez E, Lopez ON Acetylenic and allenic derivatives of 2-(5-methoxyindolyl) methylamine: Synthesis and evaluation as selective inhibitors of the monoamine oxidase A and B. Eur. J. Med. Chem. 1990 25 257–265.
   Web of Science ®Google Scholar
• McDonald IA, Palfreyman MG, Zreika M, Bey P (Z)-2-(2,4-Dichloro-phenoxy)methyl-3-fluoroallylamine (MDL 72638): A clorgyline analogue with surprising selectivity for monoamine oxidase type B. Biochem. Pharmacol. 1986 35 349–351.
   PubMed Web of Science ®Google Scholar
• McDonald IA, Lacoste JM, Bey P, Wagner J, Zreika M, Palfreyman MG Dual enzyme-activated irreversible inhibitors of monoamine oxidase. Bioorg. Chem. 1986 14 103–118.
   Web of Science ®Google Scholar
• Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A Design and early clinical evaluation of selective inhibitiors of monoamine oxidase. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988 12 967–987.
   PubMed Web of Science ®Google Scholar
• Danzin C, Collard JN, Marchal P, Schirlin D Selective inactivation of MAO-B by benzyl-dimethyl-silyl-methanamines in vitro. Biochem. Biophys. Res. Commun. 1989 160 540–544.
   PubMed Web of Science ®Google Scholar
• Waldmeier PC, Baumann PA Effects of CGP 11305A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 1983 324 20–26.
   Google Scholar
• Cesura AM, Galva MD, Imhof R, Da Prada M Binding of [3H]Ro 16–6491, a reversible inhibitor of monoamine oxidase type B, to human brain mitochondria and pletelet membranes. J. Neurochem. 1987 48 170–176.
   PubMed Web of Science ®Google Scholar
• Harfenist M, McGee DPC, White HL A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen, with negligible potentiation of tyramine-induced blood pressure rise. J. Med. Chem. 1991 34 2931–2933.
   PubMed Web of Science ®Google Scholar
• Guldberg HC, Marsden CA Catechol-O-methyl transferase: Pharmacological aspects and physiological role. Pharmacol. Rev. 1975 27 135–206 An excellent introduction into the enzyme and its inhibitors up until 1973.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Leger G, Guttman M Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: Implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 1991 14 330–342.
   PubMed Web of Science ®Google Scholar
• Zurcher G, Colzi A, Da Prada M Ro 40–7592: Inhibition of COMT in rat brain and extracerebral tissues. J. Neural Transm. Suppl. (Austria) 1990 32 375–380.
   PubMedGoogle Scholar
• Waldmeier PC, De Herdt P, Maitre L Effects of the COMT inhibitor, CGP 28014, on plasma homovaniliic acid and O-methylation of exogenous L-dopa in the rat. J. Neural Transm. Suppl. (Austria) 1990 32 381–386.
   PubMedGoogle Scholar
• Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, Von Sprecher G CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-cathechol structure. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990 342 305–311.
   Google Scholar
• Piedrafita FJ, Elorriaga C, Fernández-Alvarez E, Nieto O Inhibition of catechol-O-methyltransferase by N-(3,4-dihydroxyphenyl)-maleimide. J. Enz. Inhib. 1990 4 43–50.
   Google Scholar
• Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 1985 106 209–210.
   Web of Science ®Google Scholar
• Grima B, Lamouroux A, Boni C, Julien JF, Jauoy-Agio F, Malle J A single human gene encoding multiple tyrosine hydroxylase with different predicted functional characteristics. Nature (London) 1987 326 707–711.
   PubMed Web of Science ®Google Scholar

References to Patent Literature

References to Patent Literature

• Merrell Dow Pharm Inc, EP-451422.
   Google Scholar
• Merrell Toraude, SA, BE-86881.
   Google Scholar
• Merrell Toraude, SA, DE3012641.
   Google Scholar
• Merrell Toraude, S A, DE3012581.
   Google Scholar
• Merrell Toraude, S A, US4342780.
   Google Scholar
• Merrell Toraude, S A, GB4342780.
   Google Scholar
• Merrell Toraude, S A, DE2836674.
   Google Scholar
• Merrell Toraude, S A, DE3015360.
   Google Scholar
• Merrell Toraude, S A, DE3015373.
   Google Scholar
• Merrell Toraude, S A, BE-882104.
   Google Scholar
• Merrell Toraude, S A, FR-245277.
   Google Scholar
• Merrell Toraude, S A, BE-868596.
   Google Scholar
• Syntex (USA) Inc, EP-134561.
   Google Scholar
• Merrell Toraude, S A, EP-40150.
   Google Scholar
• Nippon Soda Co Ltd, JP59164783.
   Google Scholar
• Nippon Kayaku Co Ltd, JP54039077.
   Google Scholar
• Georgia Tech Res Corp, US4906668.
   Google Scholar
• Merrell Dow Pharmaceuticals Inc, EP-187390.
   Google Scholar
• Merrell Dow Pharmaceuticals Inc, EP-186915.
   Google Scholar
• SmithKline Beckman Corp, EP-250264.
   Google Scholar
• Merrell Dow Pharm Inc, US4743617.
   Google Scholar
• SmithKline Beckman Corp, JP62061960.
   Google Scholar
• Merrell Dow Pharm Inc, US4981868.
   Google Scholar
• SmithKline Beckman Corp, EP-125033.
   Google Scholar
• SmithKline Beckman Corp, ZA8402963.
   Google Scholar
• SmithKline Beckman Corp, ZA8402962.
   Google Scholar
• Merrell Dow Pharm Inc, AT-387967.
   Google Scholar
• Merrell Dow Pharm Inc, US5057613.
   Google Scholar
• Merrell Dow Pharm Inc, US4810800.
   Google Scholar
• SmithKline Beckman Corp, EP-371730.
   Google Scholar
• SmithKline Beckman Corp, EP-371732.
   Google Scholar
• SmithKline Beckman Corp, EP-371733.
   Google Scholar
• SmithKline Beckman Corp, EP-359505.
   Google Scholar
• SmithKline Beckman Corp, EP-323737.
   Google Scholar
• SmithKline Beckman Corp, EP-323146.
   Google Scholar
• SmithKline Beckman Corp, EP-323147.
   Google Scholar
• Eli Lilly & Co, US3781443.
   Google Scholar
• Eli Lilly & Co, US3919316.
   Google Scholar
• SmithKline Corp, US3988339.
   Google Scholar
• SmithKline Corp, US4128666.
   Google Scholar
• Eli Lilly & Co, DE2827931.
   Google Scholar
• SmithKline Corp, JP54154553.
   Google Scholar
• SmithKline Corp, US4192888.
   Google Scholar
• SmithKline Corp, US4208430.
   Google Scholar
• SmithKline Corp, US4218464.
   Google Scholar
• SmithKline Corp, US4228170.
   Google Scholar
• SmithKline Corp, US4242346.
   Google Scholar
• Consejo Superior de Investigaciones Cientificas, ES2010142.
   Google Scholar
• Consejo Superior de Investigaciones Cientificas, ES2010406.
   Google Scholar
• Merrell Dow Pharm Inc, US4699928.
   Google Scholar
• Merrell Dow Pharm Inc, US4650907.
   Google Scholar
• Merrell Dow Pharm Inc, EP-291998.
   Google Scholar
• Merrell Toraude, S A, US4421767.
   Google Scholar
• Merrell Dow Pharm Inc, US4822812.
   Google Scholar
• Merrell Dow Pharm Inc, EP-291787.
   Google Scholar
• Ciba-Geigy, AG, CH-611617.
   Google Scholar
• Delalande, S A, FR2500450.
   Google Scholar
• Delalande, S A, DE3320394.
   Google Scholar
• Delalande, S A, FR2608604.
   Google Scholar
• Delalande, S A, EP259228.
   Google Scholar
• Delalande, S A, FR2631827.
   Google Scholar
• Tanabe Seiyaku Co Ltd, EP-425209.
   Google Scholar
• Hoffmann-La Roche F und Co, AG, EP-352581.
   Google Scholar
• Hoffmann-La Roche F und Co, AG, DE3530046.
   Google Scholar
• Hoffmann-La Roche F und Co, AG, DE3407654.
   Google Scholar
• Wellcome Foundation Ltd, EP-419157.
   Google Scholar
• Orion-Yhtyma Oy, GB2220569.
   Google Scholar
• Orion-Yhtyma Oy, DE3843324.
   Google Scholar
• Orion-Yhtyma Oy, DE3740383.
   Google Scholar
• Hoffmann-La Roche F und Co, AG, AU-603788.
   Google Scholar
• Ciba-Geigy Corp, US4833938.
   Google Scholar
• Mitsui Toatsu Chem Inc, JP54066671.
   Google Scholar